Moreover, analysis of the BeatAML dataset showed that higher SCD expression correlates with reduced sensitivity in vitro to cytarabine, an antimetabolite known to cause DNA damage and used in combination with anthracyclines to treat AML patients (Supplementary Fig. 8F). This evidence concerns the gene SCD and acute myeloid leukemia.